Sjögren's Syndrome
Sjögren's syndrome (SS) results in the hallmark symptoms of dry mouth (xerostomia) and dry eyes (keratoconjunctivitis sicca). At our company, we are committed to providing advanced drug and therapy development solutions for autoimmune diseases and inflammation, including Sjögren's syndrome.
Overview of Sjögren's Syndrome
Sjögren's Syndrome is a chronic autoimmune disorder primarily affecting the exocrine glands, leading to diminished secretion of saliva and tears. Genetic predisposition plays a significant role, as evidenced by the association of specific HLA alleles, such as HLA-DRB103 and HLA-DQB102, with increased susceptibility to SS. Environmental factors, including viral infections such as Epstein-Barr virus (EBV), have been implicated in triggering the autoimmune response in susceptible individuals. Dysregulation of innate and adaptive immune responses is also involved in the pathogenesis of SS. Inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), play a crucial role in perpetuating the autoimmune process.
Fig.1 Classical risk factors of Sjögren's syndrome. (Chatzis L., et al., 2020)
Therapy Discovery and Development for Sjögren's Syndrome
Adaptive immunotherapy and targets for Sjögren's syndrome are as follows:
| Antigen presentation/Costimulation | ||
|---|---|---|
| Petesicatib (Cathepsin S) | Abatacept (CTLA4) | Lulizumab (CD28) |
| Prezalumab (ICOSL) | Iscalimab (CD40) | MR1, VIB4920 (CD40L) |
| Efalizumab/Lifitegrast (LFA1) | ||
| B-cell activation | ||
| Belimumab (BAFF) | Tibulizumab (BAFF&IL-17A) | lanalumab (BAFF-R) |
| RC18 (TACI) | Rituximab (CD20) | Tirabrutinib, Lou064 (BTK) |
| Ly9.7.144 (CD229, Ly9) | Seletalisib, Parsaclisib, CDZ173 (P3IK6) | |
| T-cell proliferation | ||
| GSK2618960 (L-7R) | rh-IL2 (Tregs expansion) | |
| Germinal center formation | ||
| Baminercept (LTbR) | ||
At our company, we are dedicated to developing diagnostics and effective therapies for Sjögren's syndrome, including small molecule drugs, biologics, and immunomodulatory agents. If you wish to acquire further insights into our groundbreaking endeavors, kindly navigate through the link provided below.
Small Molecule Drug
Probiotics Therapy
Therapeutic Antibody
Cell Therapy
Gene Therapy
Therapeutics Development
Our Services
We specialize in the development and characterization of Sjögren's syndrome animal models and in vitro models. These models serve as valuable tools for studying disease mechanisms, evaluating therapeutic interventions, and investigating the efficacy of novel candidate drugs. Our expertise in model development ensures that our clients have access to reliable and relevant platforms for their research and development needs.
- NOD (Non-Obese Diabetic) Models
- NOD.B10-H2b Models
- C57BL/6.NOD-Aec1Aec2 Models
- NFS/sld Mutant Models
- IQI/Jic Mouse Models
- Aly/aly Mouse Models
Spontaneous Animal Models
- Id3 KO Mouse Models
- PI3K KO Mouse Models
- Ar KO Mouse Models
- RbAp48 Tg Mouse Models
- Act1 KO Mouse Models
- ERdj5 KO Mouse Models
Genetically Engineered Models
- Ro60 Peptide-Induced Models
- M3R Peptide Immunization Models
- CAII Immunization Model
- MCMV-Induced Mouse Models
Induced Disease Models
- Primary Salivary Gland Epithelial Cells, Lymphocytes, and Other Relevant Cell Types.
- Co-Culture Models
- Salivary Gland Organoids
- Lacrimal Gland Organoids
In Vitro Models
Our preclinical research services focus on the development and validation of novel therapeutic approaches for Sjögren's syndrome, including drug safety evaluation and pharmacokinetic analysis. In addition to the aforementioned range of services and models, we also specialize in tailoring customized solutions and developing disease models that precisely align with your distinctive requirements. Should our array of services capture your interest, we warmly encourage you to reach out to us without hesitation.
References
- Chatzis L., et al. "Sjögren's syndrome: the clinical spectrum of male patients." Journal of clinical medicine 9.8 (2020): 2620.
- Negrini S., et al. "Sjögren's syndrome: a systemic autoimmune disease." Clinical and experimental medicine 22.1 (2022): 9-25.
- Mavragani Clio P., and Haralampos M. Moutsopoulos. "Sjögren's syndrome: old and new therapeutic targets." Journal of autoimmunity 110 (2020): 102364.